Equities

AbbVie Inc

0QCV:LSE

AbbVie Inc

  • Price (USD)221.50
  • Today's Change6.25 / 2.90%
  • Shares traded5.15k
  • 1 Year change15.59%
  • Beta0.3351
Data delayed at least 20 minutes, as of Feb 06 2026 19:09 GMT.
More ▼

Profile data is unavailable for this security.

About the company

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

  • Revenue in USD (TTM)59.64bn
  • Net income in USD2.35bn
  • Incorporated2012
  • Employees55.00k
  • Location
    AbbVie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
  • Phone+1 (847) 932-7900Fax+1 (302) 655-5049
  • Websitehttps://www.abbvie.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		0QCV:LSE since
announced		Transaction
value
West Pharmaceutical Services Inc-SmartDoseAnnounced12 Jan 202612 Jan 2026Announced0.65%112.50m
Capstan Therapeutics IncDeal completed30 Jun 202530 Jun 2025Deal completed21.50%2.10bn
Data delayed at least 20 minutes, as of Feb 06 2026 19:09 GMT.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.